Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone858-450-6464
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.43 million
Profitability
Miscellaneous
Employees47
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions
What is Crinetics Pharmaceuticals' stock symbol?
Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."
How were Crinetics Pharmaceuticals' earnings last quarter?
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) issued its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.46) by $0.05. Crinetics Pharmaceuticals had a negative return on equity of 24.12% and a negative net margin of 1,303.31%. View Crinetics Pharmaceuticals' Earnings History.
When is Crinetics Pharmaceuticals' next earnings date?
What price target have analysts set for CRNX?
3 equities research analysts have issued 12-month price objectives for Crinetics Pharmaceuticals' shares. Their forecasts range from $28.00 to $40.00. On average, they anticipate Crinetics Pharmaceuticals' stock price to reach $34.3333 in the next twelve months. This suggests a possible upside of 103.2% from the stock's current price. View Analyst Price Targets for Crinetics Pharmaceuticals.
What is the consensus analysts' recommendation for Crinetics Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crinetics Pharmaceuticals.
What are Wall Street analysts saying about Crinetics Pharmaceuticals stock?
Here are some recent quotes from research analysts about Crinetics Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's product pipeline consists of CRN00808 for the treatment of Acromegaly, CRN02481 for the treatment of Hyperinsulinemias and CRN01941 for the treatment of Neuroendocrine Tumors which are in clinical stage. Crinetics Pharmaceuticals Inc is based in San Diego, United States. " (8/16/2019)
- 2. HC Wainwright analysts commented, "Valuation; reiterate Buy rating. Our $35 price target for Crinets is based on our sum-of-the-parts NPV valuation based on each of the company’s ongoing products. Our DCF model utilizes a discount rate of 12.2% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%)." (4/16/2019)
Has Crinetics Pharmaceuticals been receiving favorable news coverage?
Media headlines about CRNX stock have trended positive recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Crinetics Pharmaceuticals earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near future. View News Stories for Crinetics Pharmaceuticals.
Are investors shorting Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals saw a drop in short interest during the month of July. As of July 31st, there was short interest totalling 2,019,500 shares, a drop of 8.6% from the June 30th total of 2,210,500 shares. Based on an average trading volume of 69,000 shares, the short-interest ratio is presently 29.3 days. Approximately 14.9% of the company's shares are short sold. View Crinetics Pharmaceuticals' Current Options Chain.
Who are some of Crinetics Pharmaceuticals' key competitors?
Some companies that are related to Crinetics Pharmaceuticals include Tricida (TCDA), Pacira Biosciences (PCRX), Turning Point Therapeutics (TPTX), Prestige Consumer Healthcare (PBH), Eidos Therapeutics (EIDX), Nabriva Therapeutics (NBRV), Corcept Therapeutics (CORT), Heron Therapeutics (HRTX), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), Enanta Pharmaceuticals (ENTA), Insmed (INSM), Ironwood Pharmaceuticals (IRWD), Ra Pharmaceuticals (RARX) and Deciphera Pharmaceuticals (DCPH).
What other stocks do shareholders of Crinetics Pharmaceuticals own?
Who are Crinetics Pharmaceuticals' key executives?
Crinetics Pharmaceuticals' management team includes the folowing people:
- Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 57)
- Mr. Marc J. C. Wilson, CFO & Sec. (Age 40)
- Dr. Alan S. Krasner, Chief Medical Officer (Age 56)
- Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 53)
When did Crinetics Pharmaceuticals IPO?
(CRNX) raised $80 million in an IPO on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.
Who are Crinetics Pharmaceuticals' major shareholders?
Crinetics Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (8.43%), BlackRock Inc. (3.86%), Vanguard Group Inc. (2.09%), Janus Henderson Group PLC (2.07%), Janus Henderson Group PLC (2.07%) and Price T Rowe Associates Inc. MD (2.02%). Company insiders that own Crinetics Pharmaceuticals stock include Alan Seth Krasner, Life Sciences Maste Perceptive, Ventures Iv LP 5Am, Vivo Capital Fund Viii, LP and Vivo Capital Viii, Llc. View Institutional Ownership Trends for Crinetics Pharmaceuticals.
Which major investors are selling Crinetics Pharmaceuticals stock?
CRNX stock was sold by a variety of institutional investors in the last quarter, including Hershey Trust Co., Morgan Stanley and BNP Paribas Arbitrage SA. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Ventures Iv LP 5Am and Vivo Capital Fund Viii, LP. View Insider Buying and Selling for Crinetics Pharmaceuticals.
Which major investors are buying Crinetics Pharmaceuticals stock?
CRNX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Orbimed Advisors LLC, Marshall Wace North America L.P., Vanguard Group Inc., Alps Advisors Inc., Swiss National Bank, Victory Capital Management Inc. and Bank of New York Mellon Corp. Company insiders that have bought Crinetics Pharmaceuticals stock in the last two years include Alan Seth Krasner, Life Sciences Maste Perceptive and Vivo Capital Viii, Llc. View Insider Buying and Selling for Crinetics Pharmaceuticals.
How do I buy shares of Crinetics Pharmaceuticals?
Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Crinetics Pharmaceuticals' stock price today?
One share of CRNX stock can currently be purchased for approximately $16.90.
How big of a company is Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals has a market capitalization of $408.98 million and generates $2.43 million in revenue each year. The company earns $-27,110,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe.View Additional Information About Crinetics Pharmaceuticals.
What is Crinetics Pharmaceuticals' official website?
How can I contact Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]
MarketBeat Community Rating for Crinetics Pharmaceuticals (NASDAQ CRNX)
MarketBeat's community ratings are surveys of what our community members think about Crinetics Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
